{"groups":[{"description":"Participants received pembrolizumab 200 mg, intravenously (IV), every 3 weeks, for one year.","id":"FG000","title":"Pembrolizumab"},{"description":"Participants received placebo, IV, every 3 weeks, for one year.","id":"FG001","title":"Placebo"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"136"},{"groupId":"FG001","numSubjects":"154"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"16"}],"type":"Withdrawal of consent"},{"reasons":[{"groupId":"FG000","numSubjects":"429"},{"groupId":"FG001","numSubjects":"415"}],"type":"Participants ongoing"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"590"},{"groupId":"FG001","numSubjects":"587"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"580"},{"groupId":"FG001","numSubjects":"581"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"590"},{"groupId":"FG001","numSubjects":"587"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"One participant randomized to the study in error did not provide informed consent and was not included. No data was collected on this participant."}